SOHM, Inc.
Other OTCRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- SOHM, Inc. is a pharmaceutical and biotechnology company headquartered in Chino Hills, California, founded in 1998. The company specializes in the development, manufacturing, marketing, and distribution of generic, branded generic, private label pharmaceuticals, cosmeceuticals, and nutraceutical products. Its portfolio includes generic drugs covering all major therapeutic categories such as analgesics, antibiotics, anti-cold, anti-inflammatory drugs, over-the-counter (OTC) products, and proprietary branded chewables like gummy vitamins and supplements targeting health and wellness. SOHM targets diverse markets including the United States and emerging regions in Africa, Latin America, and Southeast Asia, leveraging strategic manufacturing alliances primarily in India and the U.S. Recent major developments at SOHM include strategic expansions into biotechnology-driven cosmeceuticals using bioengineered actives like exosomes, peptides, and regenerative proteins, supported by advanced cell culture and fermentation techniques. The company has also advanced its gene-editing technology portfolio with its proprietary ABBIE platform, focusing on Cas9-guided integrase tools for next-generation CAR-T therapies and regenerative medicine applications. In 2025, SOHM relocated its operations to a 24,000 square-foot commercialization facility in Vista, California, to support R&D, manufacturing, and biotech commercialization efforts. Additionally, the company launched a new user-friendly website and is set to introduce an e-commerce platform for direct B2C sales of its cosmeceuticals, nutraceuticals, and OTC product lines. SOHM's operations span pharmaceutical manufacturing, contract development and manufacturing (CDMO) services, and biotechnology innovation. The company’s product offerings include Rx generic products, private label generics, OTC self-care items, advanced cosmeceuticals, and nutraceutical supplements, positioning it in fast-growing healthcare segments. Its business model combines traditional pharmaceutical manufacturing with biotechnology innovation to support drug screening, diagnostics, and health solutions globally. Overall, SOHM, Inc. stands as a diversified generic pharmaceutical and biotech company focused on expanding its product portfolio through innovative technologies and strategic market expansions, operating extensively in North America with a global distribution reach to emerging markets. The company employs approximately 23 people and reported $7 million in revenue in 2024, maintaining FDA and cGMP compliance across its manufacturing processes. This profile incorporates the latest strategic moves including its biotech cosmeceuticals launch, commercialization facility expansion, ABBIE gene-editing platform enhancements, and digital transformation efforts to elevate market engagement and sales capabilities in 2025.
SOHM Inc. Releases White Paper on ABBIE, a Cas9-Guided Integrase Enabling Stable Gene Integration and Creation of SKOV3-GYS1 Cell Line for Drug Discovery
SOHM Notes FDA's Evolving Gene-Editing Framework in Context of Ongoing ABBIE Platform Development
SOHM, Inc., Moving and Expanding Commercialization Capabilities with its New Vista, CA Facility
SOHM Achieves Breakthrough with ABBIE Gene Editing Platform, Advancing Strategic Partnership and Licensing Opportunities
SOHM, Inc. Launches New User-Friendly Website to Enhance Customer, Investor Experience and Engagement
SOHM, Inc. Appoints Ravi Kapoor as an Independent Director
SOHM, Inc. Sets Strategic Goals to Enter Biotechnology-Driven Cosmeceuticals Market
SOHM Inc. Welcomes Dr. Larissa Karnaoukhova as New Vice President of Operations
SOHM Inc. Welcomes Dr. Lucia Piccotti to Offer Expert Guidance on Cosmeceutical and Personal Health Product Research and Development
SOHM, Inc., Unveils Genetically Engineered Ovarian Cancer Cell Line Using ABBIE(TM) Platform to Accelerate GYS1 Drug Discovery
Dr. Leonardo Mirandola Joins SOHM, Inc. as an Advisory Board to Advance CAR-T Cell Projects Toward Clinical Trials and Commercialization
SOHM Inc. Awarded European Patent for Innovative ABBIE Genome Editing Technology
SOHM, Inc. Announces Patent Allowance/Approval in South Korea
SOHM, Inc. Shares an Exciting Expansion and Upcoming Presentation on ABBIE
SOHM, Inc. Launches New AI Team to Advance ABBIE System and Genome Editing Innovations
SOHM, Inc. Shares Groundbreaking Findings in ABBIE Technology
SOHM, Inc. Announce Dr. Wei Zhu Onboard as Senior Marketing and Sales Consultant
SOHM, Inc. Announces Allowances Of Japanese Patent Claims Received from Japan's Patent Office (特許庁, Tokkyochō, JPO) Protecting Transformative SOHM-ABBIE Genome Edited, SAGE Recombinant-Organisms, -Cells, -Secretomes, -Exosomes
SOHM, Inc. Continues to Build its IP Portfolio in the Gene Editing and Cell Engineering Space
SOHM, Inc. has Received ABBIE Technology Kits' Pre-Launch Pre-Orders